<!--HTML document created with Certent Powered by Crossfire 5.13.55.0-->
<!--Created on: 10/5/2015 5:22:19 AM-->
<html>
	<head>
		<title>
			8K
		</title>
	</head>
	<body><div style="margin-left:54pt;margin-right:54pt;">
		<p style="margin:0pt;border-bottom:2pt double #000000 ;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<a name="_GoBack"></a><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 16pt">
			<font style="display: inline;font-weight:bold;font-size:16pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">WASHINGTON, D.C. 20549</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font><font style="display: inline;">__________________________________</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 16pt">
			<font style="display: inline;font-weight:bold;font-size:16pt;">FORM 8-K</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font><font style="display: inline;">__________________________________</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 14pt">
			<font style="display: inline;font-weight:bold;font-size:14pt;">CURRENT REPORT</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">PURSUANT TO SECTION 13 OR 15(d) of the</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Date of Report (Date of earliest event reported): </font><font style="display: inline;font-weight:bold;">October 4</font><font style="display: inline;font-weight:bold;">, 201</font><font style="display: inline;font-weight:bold;">5</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font><font style="display: inline;">__________________________________</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 16pt">
			<font style="display: inline;font-weight:bold;font-size:16pt;">ATRICURE, INC.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">(Exact name of registrant as specified in charter)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">__________________________________</font>
		</p>
		<p style="margin:1.5pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:33.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:33.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:33.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:33.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:33.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:33.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">Delaware</font></p>
				</td>
				<td valign="top" style="width:33.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">000-51470</font></p>
				</td>
				<td valign="top" style="width:33.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">34-1940305</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:33.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">(State or other jurisdiction</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">of incorporation)</font></p>
				</td>
				<td valign="top" style="width:33.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">(Commission</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">File Number)</font></p>
				</td>
				<td valign="top" style="width:33.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">(IRS Employer</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Identification No.)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:50.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:50.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">6217 Centre Park Drive</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">West Chester, OH</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;">45069</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">(Address of principal executive offices)</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">(Zip Code)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Registrant's telephone number, including area code: (513)&nbsp;755-4100</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Not Applicable</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-weight:bold;font-size:8pt;">(Former name or former address, if changed since last report)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font><font style="display: inline;">__________________________________</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 4pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:22.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:361.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:22.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#x2610;</font></p>
				</td>
				<td valign="top" style="width:361.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 4pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:22.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:361.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:22.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#x2610;</font></p>
				</td>
				<td valign="top" style="width:361.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 4pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:22.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:450.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:22.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#x2610;</font></p>
				</td>
				<td valign="top" style="width:450.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 4pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:22.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:448.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:22.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#x2610;</font></p>
				</td>
				<td valign="top" style="width:448.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 6pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:2pt double #000000 ;border-top:1pt none #D9D9D9 ;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 14pt">

		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;font-family:Times New Roman;;font-size: 14pt"><font style="display: inline;font-size:14pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item&nbsp;1.01.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entry into a Material Definitive Agreement.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;text-decoration:underline;">Merger Agreement </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Effective October 4</font><font style="display: inline;">, 2015</font><font style="display: inline;">, AtriCure, Inc. (</font><font style="display: inline;">&#x201C;</font><font style="display: inline;text-decoration:underline;">AtriCure</font><font style="display: inline;">&#x201D;</font><font style="display: inline;"> or the &#x201C;</font><font style="display: inline;text-decoration:underline;">Company</font><font style="display: inline;">&#x201D;), </font><font style="display: inline;">nContact Surgical, Inc., a Delaware corporation (&#x201C;</font><font style="display: inline;text-decoration:underline;">nContact</font><font style="display: inline;">&#x201D;), </font><font style="display: inline;">two merger subsidiaries</font><font style="display: inline;"> of AtriCure, and</font><font style="display: inline;"> WRYP Stockholder Services, LLC</font><font style="display: inline;">, solely in its capacity as representative of the stockholders </font><font style="display: inline;">of nContact </font><font style="display: inline;">(&#x201C;</font><font style="display: inline;text-decoration:underline;">Representative</font><font style="display: inline;">&#x201D;), entered into a Merger Agreement (the &#x201C;</font><font style="display: inline;text-decoration:underline;">Merger Agreement</font><font style="display: inline;">&#x201D;). Pursuant to the Merger Agreement, </font><font style="display: inline;">on the terms and subject to the satisfaction of the conditions set forth therein, </font><font style="display: inline;">nContact</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">will </font><font style="display: inline;">merge with and into the merger subsidiaries (the &#x201C;</font><font style="display: inline;text-decoration:underline;">Merger</font><font style="display: inline;">&#x201D;) and </font><font style="display: inline;">become a wholly-owned subsidiary of AtriCure</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Subject</font><font style="display: inline;"> to its terms, t</font><font style="display: inline;">he Merger Agreement requires AtriCure to make an up-front payment of </font><font style="display: inline;">approximately 3.4 million</font><font style="display: inline;"> shares of AtriCure common stock and </font><font style="display: inline;">approximately $8 million</font><font style="display: inline;"> in cash and deposit an additional </font><font style="display: inline;">304,878 </font><font style="display: inline;">shares of common stock into an escrow established pursuant to the Merger Agreement for post-closing claims.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Subject to meeting performance</font><font style="display: inline;"> milestones throughout the four-</font><font style="display: inline;">year period beginning January&nbsp;1, 2016, as more particularly described in the Merger Agreement, nContact stockholders will be eligible to receive additional co</font><font style="display: inline;">nsideration in the form of earn-</font><font style="display: inline;">out payments (the &#x201C;</font><font style="display: inline;text-decoration:underline;">Earn-Out</font><font style="display: inline;">&#x201D;). </font><font style="display: inline;">Specifically, nContact shareholders can earn additional annual consideration if nContact revenue exceeds an annual growth rate of greater than 25%. AtriCure also is required to pay an additional $50 million&nbsp;upon completion of enrollment of nContact&#x2019;s CONVERGE IDE trial and approval </font><font style="display: inline;">of a pre-marketing approval application </font><font style="display: inline;">(PMA) from the U.S. Food and Drug Administration. </font><font style="display: inline;">The Earn-Out may be paid in a combination of cash and AtriCure common stock. The Merger Agreement provides that the maximum number of shares that may be issued by AtriCure in connection with all of the transactions contemplated by the Merger Agreement, including the Earn-Out, shall not exceed 19.9% of AtriCure&#x2019;s outstanding shares of common stock prior to the acquisition of nContact. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In connection with the Merger, at the effective time of the Merger, (i)&nbsp;each outstanding share of </font><font style="display: inline;">nContact</font><font style="display: inline;">&#x2019;s preferred stock</font><font style="display: inline;"> held by accredited investors (as that term is defined under Rule 501 of Regulation D under the Securities Act of 1933, as amended)</font><font style="display: inline;">, other than those shares with respect to which appraisal rights are properly exercised and not withdrawn, shall be converted into the right to receive the applicable </font><font style="display: inline;">Preferred </font><font style="display: inline;">Per Share Merger Consideration (as defined in the Merger Agreement)</font><font style="display: inline;">, consisting of AtriCure common stock and cash, without any interest thereon, </font><font style="display: inline;">(ii) </font><font style="display: inline;">each outstanding warrant to purchase shares of nContact&#x2019;s preferred stock held by accredited investors shall be converted into the right to receive the applicable Preferred Per Share Merger Consideration (as defined in the Merger Agreement) less the exercise price of such warrant for each share of preferred stock subject to such warrant, consisting of AtriCure common stock and cash, without any interest thereon, and (iii)</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">each outstanding share of </font><font style="display: inline;">nContact</font><font style="display: inline;">&#x2019;s common stock</font><font style="display: inline;"> held by accredited investors</font><font style="display: inline;">, other than those shares with respect to which appraisal rights are properly exercised and not withdrawn, will be converted into the right to receive the Common Per Share Merger Consideration (as defined in the Merger Agreement)</font><font style="display: inline;">,consisting of AtriCure common stock and cash,</font><font style="display: inline;"> without any interest thereon. Each </font><font style="display: inline;">share of nContact stock not held by an accredited investor and each </font><font style="display: inline;">option to purchase </font><font style="display: inline;">nContact</font><font style="display: inline;">&#x2019;s common stock that </font><font style="display: inline;">is</font><font style="display: inline;"> outstanding and unexercised immediately prior to the effective time of the Merger will be</font><font style="display: inline;"> exchanged for cash</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Consummation of the Merger is subject to certain conditions, including, among others</font><font style="display: inline;">,</font><font style="display: inline;"> (i)&nbsp;approval of the Merger by </font><font style="display: inline;">nContact</font><font style="display: inline;">&#x2019;s stockholders and (ii)&nbsp;the absence of any material adverse effect on </font><font style="display: inline;">nContact</font><font style="display: inline;">&#x2019;s business. The Merger is not conditioned upon the receipt by AtriCure of financing and AtriCure stockholder approval is not required. In</font><font style="display: inline;"> addition, each of the Company </font><font style="display: inline;">and </font><font style="display: inline;">nContact </font><font style="display: inline;">have made representations and warranties in the Merger Agreement. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to and qualified in its entirety by reference to the Merger Agreement, a copy of which is attached hereto as Exhibit 2.1 and the terms of which are incorporated herein by reference. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Merger Agreement has been included to provide investors and security holders with information regarding its terms. It is not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in the Merger Agreement were made only for purposes of that agreement and as of specific dates, were solely for the benefit of the parties to the Merger Agreement and may be subject to limitations agreed upon by the contracting parties, including qualification by confidential disclosures exchanged between the parties in connection with the execution of the Merger Agreement. The representations and warranties may have been made for the purposes of allocating contractual risk between the parties to the Merger Agreement instead of establishing these matters as facts, and may be subject to contractual standards of &#x201C;materiality&#x201D; and &#x201C;material adverse effect&#x201D; applicable to the contracting parties that differ from those applicable to investors or under applicable securities laws. Investors are not third party beneficiaries under the Merger Agreement and should not rely on the representations, warranties and covenants, or any descriptions thereof, as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, </font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"><font style="display: inline;">information concerning the subject matter of the representations, warranties and covenants may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company&#x2019;s public disclosures. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item&nbsp;2.02.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On October 4</font><font style="display: inline;">, 2015, AtriCure</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">issued a press release </font><font style="display: inline;">announcing the signing of th</font><font style="display: inline;">e Merger Agreement, along with </font><font style="display: inline;">preliminary </font><font style="display: inline;">revenue </font><font style="display: inline;">results for the third quarter ended September 30</font><font style="display: inline;">, 2015</font><font style="display: inline;">. A copy of the press release is furnished </font><font style="display: inline;">as Exhibit 99.1 of this r</font><font style="display: inline;">eport</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item&nbsp;3.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unregistered Sales of Equity Securities.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The information included in the second </font><font style="display: inline;">and third </font><font style="display: inline;">paragraph</font><font style="display: inline;">s of Item&nbsp;1.01 of this r</font><font style="display: inline;">eport is incorporated by reference into this Item&nbsp;3.02. All of the above-referenced securities are being offered and sold pursuant to the exemption provided by Section&nbsp;4(2) of the Securities Act of 1933, as amended. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 7.01&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">Regulation FD Disclosure.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On October 4</font><font style="display: inline;">, 2015, AtriCure issued a press release announcing the </font><font style="display: inline;">signing of </font><font style="display: inline;">the Merger Agreement. A copy of the press release is fur</font><font style="display: inline;">nished as Exhibit&nbsp;99.1 of this r</font><font style="display: inline;">eport.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The information under </font><font style="display: inline;">Item 2.02 and </font><font style="display: inline;">Item 7.</font><font style="display: inline;">01 and in Exhibit&nbsp;99.1 of this r</font><font style="display: inline;">eport is being furnished and shall not be deemed &#x201C;filed&#x201D; for the purpose of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#x201C;</font><font style="display: inline;text-decoration:underline;">Exchange Act</font><font style="display: inline;">&#x201D;), or otherwise subject to the liabilities of that section. The information under </font><font style="display: inline;">Item 2.02 and </font><font style="display: inline;">Item 7.01 and in Exhibit&nbsp;99.1 of this report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Forward Looking Statements </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">This Form 8-K and the press release contain</font><font style="display: inline;"> &#x201C;forward-looking statements&#x201D; within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as </font><font style="display: inline;">nContact revenue growth and clinical development milestones, and AtriCure&#x2019;s </font><font style="display: inline;">earnings estimates (including projections and guidance), other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure&#x2019;s products. Forward-looking statements are based on AtriCure&#x2019;s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure&#x2019;s control. These risks and uncertainties include </font><font style="display: inline;">risks that the nContact acquisition might not occur or if closed nContact&#x2019;s business or operations might not integrate successfully with AtriCure or add anticipated revenue or new products, </font><font style="display: inline;">the rate and degree of market acceptance of AtriCure&#x2019;s products, AtriCure&#x2019;s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure&#x2019;s products, competition from existing and new products and procedures or AtriCure&#x2019;s ability to effectively react to other risks and uncertainties described from time to time in AtriCure&#x2019;s SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">Item 9.01&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">Financial Statements and Exhibits</font><font style="display: inline;font-weight:bold;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">(d) Exhibits </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:05.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:93.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:05.28%;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:93.70%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:05.28%;padding:0pt;">
					<p style="margin:5pt 0pt;border-bottom:1pt solid #000000 ;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">No.</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:93.70%;padding:0pt;">
					<p style="margin:5pt 0pt;border-bottom:1pt solid #000000 ;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.28%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.1&nbsp;
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:93.70%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Merger </font><font style="display: inline;">Agreement dated as of October 4</font><font style="display: inline;">, 2015 among nContact Surgical, Inc., AtriCure, Inc., Portal Merger Sub, Inc., Second Portal Merger Sub, LLC and </font><font style="display: inline;">WRYP Stockholder Services, LLC,</font><font style="display: inline;"> as Representative of nContact stockholders</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.28%;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:right;font-family:Times New Roman;font-size: 6pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:94.72%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.28%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99.1&nbsp;
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:93.70%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Press Release dated October 4</font><font style="display: inline;">, 2015</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;;font-size: 10pt"><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">SIGNATURES</font>
		</p>
		<p style="margin:9pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.24%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.04%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:28.52%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.58%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:45.62%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.24%;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:28.52%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:49.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">ATRICURE, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.24%;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:28.52%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.58%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.62%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.24%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Dated:</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">October 5</font><font style="display: inline;">, 2015</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:28.52%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.58%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">By:</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.62%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">/s/ M. Andrew Wade</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.24%;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:28.52%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.58%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.62%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">M. Andrew Wade</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.24%;padding:0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:16.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:28.52%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:03.58%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:45.62%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Senior Vice President and Chief Financial Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">6349414.5</font>
		</p>
		<p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "atrc-20151005x8k.htm", "description": "8-K", "secsgml_size_bytes": 55588}]
{"company-data": {"conformed-name": "AtriCure, Inc.", "cik": "0001323885", "assigned-sic": "3841", "irs-number": "341940305", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51470", "film-number": "151142031"}, "business-address": {"street1": "6217 CENTRE PARK DRIVE", "city": "WEST CHESTER", "state": "OH", "zip": "45069", "phone": "513-755-4107"}, "mail-address": {"street1": "6217 CENTRE PARK DRIVE", "city": "WEST CHESTER", "state": "OH", "zip": "45069"}}
8K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________
FORM 8-K
__________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
October 4
, 201
5
__________________________________
ATRICURE, INC.
(Exact name of registrant as specified in charter)
__________________________________
Delaware
000-51470
34-1940305
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
6217 Centre Park Drive
West Chester, OH
45069
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (513) 755-4100
Not Applicable
(Former name or former address, if changed since last report)
__________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01.     Entry into a Material Definitive Agreement.
Merger Agreement
Effective October 4
, 2015
, AtriCure, Inc. (
"
AtriCure
"
or the "
Company
"),
nContact Surgical, Inc., a Delaware corporation ("
nContact
"),
two merger subsidiaries
of AtriCure, and
WRYP Stockholder Services, LLC
, solely in its capacity as representative of the stockholders
of nContact
("
Representative
"), entered into a Merger Agreement (the "
Merger Agreement
"). Pursuant to the Merger Agreement,
on the terms and subject to the satisfaction of the conditions set forth therein,
nContact
will
merge with and into the merger subsidiaries (the "
Merger
") and
become a wholly-owned subsidiary of AtriCure
.
Subject
to its terms, t
he Merger Agreement requires AtriCure to make an up-front payment of
approximately 3.4 million
shares of AtriCure common stock and
approximately $8 million
in cash and deposit an additional
304,878
shares of common stock into an escrow established pursuant to the Merger Agreement for post-closing claims.
Subject to meeting performance
milestones throughout the four-
year period beginning January 1, 2016, as more particularly described in the Merger Agreement, nContact stockholders will be eligible to receive additional co
nsideration in the form of earn-
out payments (the "
Earn-Out
").
Specifically, nContact shareholders can earn additional annual consideration if nContact revenue exceeds an annual growth rate of greater than 25%. AtriCure also is required to pay an additional $50 million upon completion of enrollment of nContact's CONVERGE IDE trial and approval
of a pre-marketing approval application
(PMA) from the U.S. Food and Drug Administration.
The Earn-Out may be paid in a combination of cash and AtriCure common stock. The Merger Agreement provides that the maximum number of shares that may be issued by AtriCure in connection with all of the transactions contemplated by the Merger Agreement, including the Earn-Out, shall not exceed 19.9% of AtriCure's outstanding shares of common stock prior to the acquisition of nContact.
In connection with the Merger, at the effective time of the Merger, (i) each outstanding share of
nContact
's preferred stock
held by accredited investors (as that term is defined under Rule 501 of Regulation D under the Securities Act of 1933, as amended)
, other than those shares with respect to which appraisal rights are properly exercised and not withdrawn, shall be converted into the right to receive the applicable
Preferred
Per Share Merger Consideration (as defined in the Merger Agreement)
, consisting of AtriCure common stock and cash, without any interest thereon,
(ii)
each outstanding warrant to purchase shares of nContact's preferred stock held by accredited investors shall be converted into the right to receive the applicable Preferred Per Share Merger Consideration (as defined in the Merger Agreement) less the exercise price of such warrant for each share of preferred stock subject to such warrant, consisting of AtriCure common stock and cash, without any interest thereon, and (iii)
each outstanding share of
nContact
's common stock
held by accredited investors
, other than those shares with respect to which appraisal rights are properly exercised and not withdrawn, will be converted into the right to receive the Common Per Share Merger Consideration (as defined in the Merger Agreement)
,consisting of AtriCure common stock and cash,
without any interest thereon. Each
share of nContact stock not held by an accredited investor and each
option to purchase
nContact
's common stock that
is
outstanding and unexercised immediately prior to the effective time of the Merger will be
exchanged for cash
.
Consummation of the Merger is subject to certain conditions, including, among others
,
(i) approval of the Merger by
nContact
's stockholders and (ii) the absence of any material adverse effect on
nContact
's business. The Merger is not conditioned upon the receipt by AtriCure of financing and AtriCure stockholder approval is not required. In
addition, each of the Company
and
nContact
have made representations and warranties in the Merger Agreement.
The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to and qualified in its entirety by reference to the Merger Agreement, a copy of which is attached hereto as Exhibit 2.1 and the terms of which are incorporated herein by reference.
The Merger Agreement has been included to provide investors and security holders with information regarding its terms. It is not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in the Merger Agreement were made only for purposes of that agreement and as of specific dates, were solely for the benefit of the parties to the Merger Agreement and may be subject to limitations agreed upon by the contracting parties, including qualification by confidential disclosures exchanged between the parties in connection with the execution of the Merger Agreement. The representations and warranties may have been made for the purposes of allocating contractual risk between the parties to the Merger Agreement instead of establishing these matters as facts, and may be subject to contractual standards of "materiality" and "material adverse effect" applicable to the contracting parties that differ from those applicable to investors or under applicable securities laws. Investors are not third party beneficiaries under the Merger Agreement and should not rely on the representations, warranties and covenants, or any descriptions thereof, as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover,
information concerning the subject matter of the representations, warranties and covenants may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company's public disclosures.
Item 2.02.     Results of Operations and Financial Condition.
On October 4
, 2015, AtriCure
issued a press release
announcing the signing of th
e Merger Agreement, along with
preliminary
revenue
results for the third quarter ended September 30
, 2015
. A copy of the press release is furnished
as Exhibit 99.1 of this r
eport
.
Item 3.02     Unregistered Sales of Equity Securities.
The information included in the second
and third
paragraph
s of Item 1.01 of this r
eport is incorporated by reference into this Item 3.02. All of the above-referenced securities are being offered and sold pursuant to the exemption provided by Section 4(2) of the Securities Act of 1933, as amended.
Item 7.01
Regulation FD Disclosure.
On October 4
, 2015, AtriCure issued a press release announcing the
signing of
the Merger Agreement. A copy of the press release is fur
nished as Exhibit 99.1 of this r
eport.
The information under
Item 2.02 and
Item 7.
01 and in Exhibit 99.1 of this r
eport is being furnished and shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "
Exchange Act
"), or otherwise subject to the liabilities of that section. The information under
Item 2.02 and
Item 7.01 and in Exhibit 99.1 of this report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Forward Looking Statements
This Form 8-K and the press release contain
"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as
nContact revenue growth and clinical development milestones, and AtriCure's
earnings estimates (including projections and guidance), other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure's products. Forward-looking statements are based on AtriCure's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control. These risks and uncertainties include
risks that the nContact acquisition might not occur or if closed nContact's business or operations might not integrate successfully with AtriCure or add anticipated revenue or new products,
the rate and degree of market acceptance of AtriCure's products, AtriCure's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure's products, competition from existing and new products and procedures or AtriCure's ability to effectively react to other risks and uncertainties described from time to time in AtriCure's SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
Item 9.01
Financial Statements and Exhibits
.
(d) Exhibits
No.
Description
2.1
Merger
Agreement dated as of October 4
, 2015 among nContact Surgical, Inc., AtriCure, Inc., Portal Merger Sub, Inc., Second Portal Merger Sub, LLC and
WRYP Stockholder Services, LLC,
as Representative of nContact stockholders
99.1
Press Release dated October 4
, 2015
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ATRICURE, INC.
Dated:
October 5
, 2015
By:
/s/ M. Andrew Wade
M. Andrew Wade
Senior Vice President and Chief Financial Officer
6349414.5